2026 Q1 -tulosraportti
Vain PDF
69 päivää sitten
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 22.10.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·17 t sitten · MuokattuFollowing yesterday's news, regarding the approval of the bill, in the Bundestag. As I wrote yesterday, this approval will not affect Weeco Astrum10-10, and here is the explanation. I read several articles, and in none of them was the Weeco Astrum10-10 consequence mentioned. I wondered about that, so I made one of the journalists aware that Weeco Astrum10-10 is also approved in Germany. To make a long story short, it ended with me having to prove that Weeco Astrum10-10 is approved in Germany. A few hours later, I found out that even in this area, it is not normal, in Germany. Because I found out that there are several different approvals in Germany, tsk tsk tsk. Nothing is so bad that it isn't good for something else, because it has turned out to be an advantage for Weeco Astrum10-10 not to be approved for anything specific. The explanation follows below. When exactly these four different preparations are mentioned in all the articles, it is because these preparations are approved for specific diseases. e.g. Sativex is specifically approved for one particular disease, multiple sclerosis (MS), and doctors may in principle only prescribe Sativex for this disease, and the others are specifically approved for something else and may only be prescribed for that. These four preparations have all gone the hard way, with phase 1, 2 and 3. Therefore, doctors may prescribe these preparations as a first choice. Weeco Astrum10-10 is not approved for any specific diseases. This is why doctors may not start by prescribing Weeco Astrum10-10, but only when it has been shown that the other products do not work. And because Weeco Astrum10-10 is not approved for any specific disease, doctors may write prescriptions for Weeco Astrum10-10 for all diseases that are approved for cannabis medicine. Therefore, this bill, which was discussed yesterday, has no impact on the sale of Weeco Astrum10-10. The people who have received prescriptions for Weeco Astrum10-10 will continue to do so. But those who pay themselves may get a prescription immediately, and therefore do not have to wait 6 months. If you have managed to read this post before I have corrected it, then these 4 preparations have retained their status, that doctors may prescribe prescriptions as a first choice.If it's as simple as you write, then Stenocare could promote Astrum10-10 itself in Germany. Firstly, it is Stenocare that I hold shares in, and therefore I only write about Stenocare's products, and secondly, only these 4 products mentioned in the article are registered in the BfArM register and the Lauer-Taxes register; the other cannabis products, including Weeco Astrum10-10, are only registered in the Lauer-Taxe register. I have argued why the bill will not affect Weeco Astrum10-10. If you think otherwise, then I think you should argue why the bill will have any impact on Weeco Astrum10-10's earnings, instead of claiming that I'm mixing things up; no one can make sense of that, not even me. But I would like to add another reason why Weeco Astrum10-10 will not be affected by the bill, because the people who receive a prescription now have already gone through a long process and therefore the 6 months have already passed. If it turns out that I have mixed something up, as you write, then this must naturally come to light, but you must provide something concrete so that it can be corrected if it turns out that I have misunderstood something.- ·23 t sittenstock status When it became known that flowers and vapes would lose their subsidy, as of January 1, 2027, I wrote that I would keep an eye on some online stores that only have flowers and vapes in their assortment, to find out if they start to stock oils and extracts. The reason this is interesting for us is that if they start to have oils in their assortment, it's only because they expect flowers to go down and oils to go up in earnings. Canation.com: has prepared to stock oils. Canation has until now only stocked flowers, but now they are preparing to also stock oils and extracts. As I wrote earlier, Weeco Pharma has a big campaign this summer, after it became known that the subsidy stops. The campaign is targeted at companies that only stock flowers, because Weeco Pharma wants Weeco Astrum10-10 to also become part of their assortment. As I wrote, the others also have such a campaign running. Flowers and vapes have been a huge business in Germany, and therefore Canation has only had flowers in their assortment, so when they prepare to also have oils and extracts in their assortment, it means that they expect the flower business to go down and oil to go up. That was the first of the online stores that I follow. Just for the record, we don't know which brand(s) they have chosen to stock yet.
- ·10.7.I only discovered this today. Weeco Pharma has been at the EU's largest cannabis fair for professionals such as pharmacists and dealers. Weeco Astrum10-10 was part of their campaign already at the fair, which may be the reason why it has been possible for Weeco Pharma that so many doctors, in such a short time, have become aware of the oil. https://weeco.com/en/2026/02/13/weeco-will-be-present-at-the-icbc-in-berlin-on-april-13th-and-15th/It's also nothing new that there is risk in investing in stocks, and that applies to all stocks, there are no safe stocks, see what has happened with Novo Nordisk, just to give an example of a stock that was considered a safe investment. The only thing I am impatient about is to find out how much Stenocare has earned in Q2, in Germany. Tomorrow it will be 14 days since Q2 closed, and since both pharmacies and the various distributors have been digitized in Germany, Weeco Pharma must soon have finished calculating what Stenocare has earned in Germany. Regardless of the amount's size, it is much more than TS and PJ have announced, since they have stated that there will be 0 kr. in earnings from Germany in 2026.
- ·6.7.A little statistics while we wait for Weeco to get signed with Stenocare. In 2025, more than 6,900 liters of cannabis oils and extracts were sold, and it is expected that this will be increasing in 2026. When I have this converted to 30 ml bottles, with the help of AI, it amounts to 230,000 bottles in 2025. Bearing in mind that the subsidy is taken from flowers and vaporizers, https://www.insight-health.de/deu_en/our-solututions/specialty-therapeutics/medical-cannabis.html
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
Vain PDF
69 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·17 t sitten · MuokattuFollowing yesterday's news, regarding the approval of the bill, in the Bundestag. As I wrote yesterday, this approval will not affect Weeco Astrum10-10, and here is the explanation. I read several articles, and in none of them was the Weeco Astrum10-10 consequence mentioned. I wondered about that, so I made one of the journalists aware that Weeco Astrum10-10 is also approved in Germany. To make a long story short, it ended with me having to prove that Weeco Astrum10-10 is approved in Germany. A few hours later, I found out that even in this area, it is not normal, in Germany. Because I found out that there are several different approvals in Germany, tsk tsk tsk. Nothing is so bad that it isn't good for something else, because it has turned out to be an advantage for Weeco Astrum10-10 not to be approved for anything specific. The explanation follows below. When exactly these four different preparations are mentioned in all the articles, it is because these preparations are approved for specific diseases. e.g. Sativex is specifically approved for one particular disease, multiple sclerosis (MS), and doctors may in principle only prescribe Sativex for this disease, and the others are specifically approved for something else and may only be prescribed for that. These four preparations have all gone the hard way, with phase 1, 2 and 3. Therefore, doctors may prescribe these preparations as a first choice. Weeco Astrum10-10 is not approved for any specific diseases. This is why doctors may not start by prescribing Weeco Astrum10-10, but only when it has been shown that the other products do not work. And because Weeco Astrum10-10 is not approved for any specific disease, doctors may write prescriptions for Weeco Astrum10-10 for all diseases that are approved for cannabis medicine. Therefore, this bill, which was discussed yesterday, has no impact on the sale of Weeco Astrum10-10. The people who have received prescriptions for Weeco Astrum10-10 will continue to do so. But those who pay themselves may get a prescription immediately, and therefore do not have to wait 6 months. If you have managed to read this post before I have corrected it, then these 4 preparations have retained their status, that doctors may prescribe prescriptions as a first choice.If it's as simple as you write, then Stenocare could promote Astrum10-10 itself in Germany. Firstly, it is Stenocare that I hold shares in, and therefore I only write about Stenocare's products, and secondly, only these 4 products mentioned in the article are registered in the BfArM register and the Lauer-Taxes register; the other cannabis products, including Weeco Astrum10-10, are only registered in the Lauer-Taxe register. I have argued why the bill will not affect Weeco Astrum10-10. If you think otherwise, then I think you should argue why the bill will have any impact on Weeco Astrum10-10's earnings, instead of claiming that I'm mixing things up; no one can make sense of that, not even me. But I would like to add another reason why Weeco Astrum10-10 will not be affected by the bill, because the people who receive a prescription now have already gone through a long process and therefore the 6 months have already passed. If it turns out that I have mixed something up, as you write, then this must naturally come to light, but you must provide something concrete so that it can be corrected if it turns out that I have misunderstood something.
- ·23 t sittenstock status When it became known that flowers and vapes would lose their subsidy, as of January 1, 2027, I wrote that I would keep an eye on some online stores that only have flowers and vapes in their assortment, to find out if they start to stock oils and extracts. The reason this is interesting for us is that if they start to have oils in their assortment, it's only because they expect flowers to go down and oils to go up in earnings. Canation.com: has prepared to stock oils. Canation has until now only stocked flowers, but now they are preparing to also stock oils and extracts. As I wrote earlier, Weeco Pharma has a big campaign this summer, after it became known that the subsidy stops. The campaign is targeted at companies that only stock flowers, because Weeco Pharma wants Weeco Astrum10-10 to also become part of their assortment. As I wrote, the others also have such a campaign running. Flowers and vapes have been a huge business in Germany, and therefore Canation has only had flowers in their assortment, so when they prepare to also have oils and extracts in their assortment, it means that they expect the flower business to go down and oil to go up. That was the first of the online stores that I follow. Just for the record, we don't know which brand(s) they have chosen to stock yet.
- ·10.7.I only discovered this today. Weeco Pharma has been at the EU's largest cannabis fair for professionals such as pharmacists and dealers. Weeco Astrum10-10 was part of their campaign already at the fair, which may be the reason why it has been possible for Weeco Pharma that so many doctors, in such a short time, have become aware of the oil. https://weeco.com/en/2026/02/13/weeco-will-be-present-at-the-icbc-in-berlin-on-april-13th-and-15th/It's also nothing new that there is risk in investing in stocks, and that applies to all stocks, there are no safe stocks, see what has happened with Novo Nordisk, just to give an example of a stock that was considered a safe investment. The only thing I am impatient about is to find out how much Stenocare has earned in Q2, in Germany. Tomorrow it will be 14 days since Q2 closed, and since both pharmacies and the various distributors have been digitized in Germany, Weeco Pharma must soon have finished calculating what Stenocare has earned in Germany. Regardless of the amount's size, it is much more than TS and PJ have announced, since they have stated that there will be 0 kr. in earnings from Germany in 2026.
- ·6.7.A little statistics while we wait for Weeco to get signed with Stenocare. In 2025, more than 6,900 liters of cannabis oils and extracts were sold, and it is expected that this will be increasing in 2026. When I have this converted to 30 ml bottles, with the help of AI, it amounts to 230,000 bottles in 2025. Bearing in mind that the subsidy is taken from flowers and vaporizers, https://www.insight-health.de/deu_en/our-solututions/specialty-therapeutics/medical-cannabis.html
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 22.10.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
2026 Q1 -tulosraportti
Vain PDF
69 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 22.10.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·17 t sitten · MuokattuFollowing yesterday's news, regarding the approval of the bill, in the Bundestag. As I wrote yesterday, this approval will not affect Weeco Astrum10-10, and here is the explanation. I read several articles, and in none of them was the Weeco Astrum10-10 consequence mentioned. I wondered about that, so I made one of the journalists aware that Weeco Astrum10-10 is also approved in Germany. To make a long story short, it ended with me having to prove that Weeco Astrum10-10 is approved in Germany. A few hours later, I found out that even in this area, it is not normal, in Germany. Because I found out that there are several different approvals in Germany, tsk tsk tsk. Nothing is so bad that it isn't good for something else, because it has turned out to be an advantage for Weeco Astrum10-10 not to be approved for anything specific. The explanation follows below. When exactly these four different preparations are mentioned in all the articles, it is because these preparations are approved for specific diseases. e.g. Sativex is specifically approved for one particular disease, multiple sclerosis (MS), and doctors may in principle only prescribe Sativex for this disease, and the others are specifically approved for something else and may only be prescribed for that. These four preparations have all gone the hard way, with phase 1, 2 and 3. Therefore, doctors may prescribe these preparations as a first choice. Weeco Astrum10-10 is not approved for any specific diseases. This is why doctors may not start by prescribing Weeco Astrum10-10, but only when it has been shown that the other products do not work. And because Weeco Astrum10-10 is not approved for any specific disease, doctors may write prescriptions for Weeco Astrum10-10 for all diseases that are approved for cannabis medicine. Therefore, this bill, which was discussed yesterday, has no impact on the sale of Weeco Astrum10-10. The people who have received prescriptions for Weeco Astrum10-10 will continue to do so. But those who pay themselves may get a prescription immediately, and therefore do not have to wait 6 months. If you have managed to read this post before I have corrected it, then these 4 preparations have retained their status, that doctors may prescribe prescriptions as a first choice.If it's as simple as you write, then Stenocare could promote Astrum10-10 itself in Germany. Firstly, it is Stenocare that I hold shares in, and therefore I only write about Stenocare's products, and secondly, only these 4 products mentioned in the article are registered in the BfArM register and the Lauer-Taxes register; the other cannabis products, including Weeco Astrum10-10, are only registered in the Lauer-Taxe register. I have argued why the bill will not affect Weeco Astrum10-10. If you think otherwise, then I think you should argue why the bill will have any impact on Weeco Astrum10-10's earnings, instead of claiming that I'm mixing things up; no one can make sense of that, not even me. But I would like to add another reason why Weeco Astrum10-10 will not be affected by the bill, because the people who receive a prescription now have already gone through a long process and therefore the 6 months have already passed. If it turns out that I have mixed something up, as you write, then this must naturally come to light, but you must provide something concrete so that it can be corrected if it turns out that I have misunderstood something.
- ·23 t sittenstock status When it became known that flowers and vapes would lose their subsidy, as of January 1, 2027, I wrote that I would keep an eye on some online stores that only have flowers and vapes in their assortment, to find out if they start to stock oils and extracts. The reason this is interesting for us is that if they start to have oils in their assortment, it's only because they expect flowers to go down and oils to go up in earnings. Canation.com: has prepared to stock oils. Canation has until now only stocked flowers, but now they are preparing to also stock oils and extracts. As I wrote earlier, Weeco Pharma has a big campaign this summer, after it became known that the subsidy stops. The campaign is targeted at companies that only stock flowers, because Weeco Pharma wants Weeco Astrum10-10 to also become part of their assortment. As I wrote, the others also have such a campaign running. Flowers and vapes have been a huge business in Germany, and therefore Canation has only had flowers in their assortment, so when they prepare to also have oils and extracts in their assortment, it means that they expect the flower business to go down and oil to go up. That was the first of the online stores that I follow. Just for the record, we don't know which brand(s) they have chosen to stock yet.
- ·10.7.I only discovered this today. Weeco Pharma has been at the EU's largest cannabis fair for professionals such as pharmacists and dealers. Weeco Astrum10-10 was part of their campaign already at the fair, which may be the reason why it has been possible for Weeco Pharma that so many doctors, in such a short time, have become aware of the oil. https://weeco.com/en/2026/02/13/weeco-will-be-present-at-the-icbc-in-berlin-on-april-13th-and-15th/It's also nothing new that there is risk in investing in stocks, and that applies to all stocks, there are no safe stocks, see what has happened with Novo Nordisk, just to give an example of a stock that was considered a safe investment. The only thing I am impatient about is to find out how much Stenocare has earned in Q2, in Germany. Tomorrow it will be 14 days since Q2 closed, and since both pharmacies and the various distributors have been digitized in Germany, Weeco Pharma must soon have finished calculating what Stenocare has earned in Germany. Regardless of the amount's size, it is much more than TS and PJ have announced, since they have stated that there will be 0 kr. in earnings from Germany in 2026.
- ·6.7.A little statistics while we wait for Weeco to get signed with Stenocare. In 2025, more than 6,900 liters of cannabis oils and extracts were sold, and it is expected that this will be increasing in 2026. When I have this converted to 30 ml bottles, with the help of AI, it amounts to 230,000 bottles in 2025. Bearing in mind that the subsidy is taken from flowers and vaporizers, https://www.insight-health.de/deu_en/our-solututions/specialty-therapeutics/medical-cannabis.html
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt